Caplin Point Laboratories share news, announcements and annual reports
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Caplin Point Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1995 on BSE, Jun 2014 on NSE
Last close ₹2,376.10up ₹13.30 (0.56%)BSE ₹2,373.60
Share price at the NSE close on 29 Oct 2026. Previous close ₹2,362.80.
29 Oct: open ₹2,356.20, high ₹2,409.90, low ₹2,344.10
52-week range of traded prices to 29 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18,061 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.15
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.04
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 85,55750.9% delivered
Caplin Point Laboratories share news and announcements
492 announcements, routine notices left out, newest first. Page 5 of 10.
Aug 2022
2 Aug · Legal
The exchange asked on 1 Aug 2022
2 Aug · Analysts
Jul 2022
Jun 2022
2 Jun · Related Party Transaction
May 2022
19 May · Legal
The exchange asked on 19 May 2022
17 May · Corporate action
12 May · General updates
12 May · Dividend
12 May · Results
9 May · Analysts
Apr 2022
8 Apr · Annual Disclosure
Feb 2022
3 Feb · Disclosure
3 Feb · Results
1 Feb · Analysts
Jan 2022
28 Jan · Board meeting
Nov 2021
3 Nov · Disclosure
2 Nov · Results
Oct 2021
30 Oct · Analysts
27 Oct · Board meeting
Sep 2021
28 Sep · Meeting
Aug 2021
5 Aug · Results
4 Aug · Analysts
Jul 2021
Jun 2021
May 2021
8 May · Corporate action
6 May · Legal
Exchange has sought clarification from Caplin Point Laboratories Limited with respect to announcement dated 06-May-2021, regarding outcome of its Board meeting held on 06-May-2021. On basis of above the Company is required to clarify following: 1. Brief details of any governmental or regulatory approvals required for the acquisition;2. Cost of acquisition or the price at which the shares are acquired;3. Nature of consideration - whether cash consideration or share swap and details of the same;The response of the Company is awaited.6 May · Management
6 May · Analysts
6 May · Results
Apr 2021